Investigational drug · Phase 3
DW4421
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Erosive Reflux Disease, GERD (Gastroesophageal Reflux Disease).
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
7
Any phase or sponsor naming "DW4421"
First trial start
2025
Nov 17, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DW4421", any sponsor or status.
Conditions studied
As listed on its trial records.
- Erosive Reflux Disease
- GERD (Gastroesophageal Reflux Disease)
Approved drugs for the same conditions: Stomach and esophageal cancer · Acid reflux (GERD) · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "DW4421" as an intervention, largest first.
- Clinical Trial to Evaluate the Safety and Efficacy of DW4421 in Patients With Erosive Reflux DiseasePivotal-lookingCompleted
Daewon Pharmaceutical Co., Ltd.Industry
NCT07931521 · 328 participants · Start Nov 17, 2025 · Primary completion Aug 31, 2026
Drug: DW4421 20mg; DW4421 40mg and 1 more · For: Erosive Reflux Disease; GERD (Gastroesophageal Reflux Disease)
Sites: Seoul, South Korea
- A Phase 1 Clinical Trial to Evaluate the Safety and DDI of DW4421 and 3 NSAIDsPivotal-lookingRecruiting
Daewon Pharmaceutical Co., Ltd.Industry
NCT07343245 · 150 participants (planned) · Start Dec 1, 2025 · Primary completion Feb 22, 2026
Drug: DW4421; DW4421-N1 and 2 more · For: Healthy Adult
Sites: Cheongju-si, South Korea
- Multiple Ascending Dose Study of DW4421Not yet recruiting
Daewon Pharmaceutical Co., Ltd.Industry
NCT07691242 · 56 participants (planned) · Start Sep 2026 · Primary completion Dec 2026
Drug: DW4421S-T0; DW4421S-T2 and 4 more · For: Healthy Adult Volunteers
Sites: Cheongju-si, South Korea
- A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetics of DW4421-T1 and DW4421S-T1 in Healthy Adult VolunteersNot yet recruiting
Daewon Pharmaceutical Co., Ltd.Industry
NCT07364851 · 38 participants (planned) · Start Mar 6, 2026 · Primary completion May 30, 2026
Drug: DW4421-T1; DW4421S-T1 · For: Healthy Adult Volunteer
Sites: Cheongju-si, South Korea
- A Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetics of DW4421 and DW4421S in Healthy Adult VolunteersEnrolling by invitation
Daewon Pharmaceutical Co., Ltd.Industry
NCT07364877 · 38 participants (planned) · Start Dec 28, 2025 · Primary completion Mar 19, 2026
Drug: DW4421; DW4421S · For: Healthy Adult Volunteer
Sites: Cheongju-si, South Korea
- Drug-Drug Interaction Between DW4421 and Amoxicillin/ClarithromycinNot yet recruiting
Daewon Pharmaceutical Co., Ltd.Industry
NCT07382661 · 36 participants (planned) · Start Feb 2026 · Primary completion May 2026
Drug: DW4421; DW4421-1 and 1 more · For: Healthy Adult Volunteers
Sites: Cheongju-si, South Korea
Daewon Pharmaceutical Co., Ltd.Industry
NCT07364838 · 24 participants · Start Nov 21, 2024 · Primary completion Apr 8, 2025
Drug: DW4421 · For: GERD (Gastroesophageal Reflux Disease)
Sites: Cheongju-si, South Korea
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.